The standard semaglutide dosing protocol begins at 0.25 mg weekly, with gradual increases over 16 weeks to reach maintenance doses of 1.7 to 2.4 mg
10.1016/j.nbd.2016.10.003 67 PongjitK.ChanvorachoteP
Additionally, the lack of federal regulatory oversight around compounded peptide products which are not subject to the same strict manufacturing and purity standards as FDA-approved drugs allows for safety concerns, such as potential risks of sterility issues, inaccurate dosages, unknown side effects, and product contamination
Badian RA, Ekman L, Pripp AH, et al
Compounding pharmacy name(s): Not publicly named in Omzo's consumer-facing materials as of June 2026
Mostly these mixed foci consist of both basophilic and eosinophilic/clear type cells